Durvalumab Pre, Post Surgery in NSCLC: Practice Changing? Durvalumab Pre, Post Surgery in NSCLC: Practice Changing?

The AEGEAN trial is the second phase 3 study, after Checkmate 816, to demonstrate a benefit from neoadjuvant immunotherapy for patients with resectable non –small cell lung cancer.Medscape Medical News
Source: Medscape Hematology-Oncology Headlines - Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news